Adrenocortical carcinoma cost-effectiveness of therapy: Difference between revisions
No edit summary |
Iqra Qamar (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
== Overview == | |||
Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years and surveillance intervals may be increased to 6 months for the next 5 years. Surveillance includes [[cross-sectional]] [[imaging]] of [[chest]], [[abdomen]], and [[pelvis]], the use of [[FDG-PET]] for [[lesions]] of an unclear nature, laboratory evaluation for [[steroid hormones]] and evaluation of side effects in case of [[adjuvant]] [[mitotane]] [[Therapy|therapy.]] | |||
== Cost-effectiveness of therapy: == | |||
__NOTOC__ | __NOTOC__ | ||
{{Adrenocortical carcinoma}} | {{Adrenocortical carcinoma}} | ||
* Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. | |||
* Surveillance intervals may be increased to 6 months for the next 5 years. | |||
Surveillance should also include: | * Surveillance should also include: | ||
* Cross-sectional imaging of chest, abdomen, and pelvis | ** [[Cross-sectional]] [[imaging]] of [[chest]], [[abdomen]], and [[pelvis]] | ||
* The use of FDG-PET for lesions of an unclear nature | ** The use of [[FDG-PET]] for [[lesions]] of an unclear nature | ||
* Laboratory evaluation for steroid hormones | ** Laboratory evaluation for [[steroid hormones]] | ||
* Evaluation | ** Evaluation of side effects is also important in case of [[adjuvant]] [[mitotane]] [[therapy]] | ||
==References== | ==References== | ||
Revision as of 15:06, 2 October 2017
Overview
Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years and surveillance intervals may be increased to 6 months for the next 5 years. Surveillance includes cross-sectional imaging of chest, abdomen, and pelvis, the use of FDG-PET for lesions of an unclear nature, laboratory evaluation for steroid hormones and evaluation of side effects in case of adjuvant mitotane therapy.
Cost-effectiveness of therapy:
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma cost-effectiveness of therapy |
|
FDA on Adrenocortical carcinoma cost-effectiveness of therapy |
|
CDC on Adrenocortical carcinoma cost-effectiveness of therapy |
|
Adrenocortical carcinoma cost-effectiveness of therapy in the news |
|
Blogs on Adrenocortical carcinoma cost-effectiveness of therapy |
|
Risk calculators and risk factors for Adrenocortical carcinoma cost-effectiveness of therapy |
- Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years.
- Surveillance intervals may be increased to 6 months for the next 5 years.
- Surveillance should also include: